[go: up one dir, main page]

FI970198L - Ihmisen immuunikatoviruksen vastaiset neutraloivat ihmisen monoklonaaliset vasta-aineet - Google Patents

Ihmisen immuunikatoviruksen vastaiset neutraloivat ihmisen monoklonaaliset vasta-aineet Download PDF

Info

Publication number
FI970198L
FI970198L FI970198A FI970198A FI970198L FI 970198 L FI970198 L FI 970198L FI 970198 A FI970198 A FI 970198A FI 970198 A FI970198 A FI 970198A FI 970198 L FI970198 L FI 970198L
Authority
FI
Finland
Prior art keywords
monoclonal antibodies
antibodies against
immunodeficiency virus
neutralizing
human immunodeficiency
Prior art date
Application number
FI970198A
Other languages
English (en)
Swedish (sv)
Other versions
FI970198A7 (fi
FI970198A0 (fi
Inventor
Dennis R Burton
Carlos F Barbas
Richard A Lerner
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of FI970198A0 publication Critical patent/FI970198A0/fi
Publication of FI970198L publication Critical patent/FI970198L/fi
Publication of FI970198A7 publication Critical patent/FI970198A7/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Socks And Pantyhose (AREA)
  • Knitting Of Fabric (AREA)
FI970198A 1994-07-18 1995-07-11 Ihmisen immuunikatoviruksen vastaiset neutraloivat ihmisen monoklonaal iset vasta-aineet FI970198A7 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/276,852 US5652138A (en) 1992-09-30 1994-07-18 Human neutralizing monoclonal antibodies to human immunodeficiency virus
PCT/US1995/008743 WO1996002273A1 (en) 1994-07-18 1995-07-11 Human neutralizing monoclonal antibodies to human immunodeficiency virus

Publications (3)

Publication Number Publication Date
FI970198A0 FI970198A0 (fi) 1997-01-17
FI970198L true FI970198L (fi) 1997-03-17
FI970198A7 FI970198A7 (fi) 1997-03-17

Family

ID=23058336

Family Applications (1)

Application Number Title Priority Date Filing Date
FI970198A FI970198A7 (fi) 1994-07-18 1995-07-11 Ihmisen immuunikatoviruksen vastaiset neutraloivat ihmisen monoklonaal iset vasta-aineet

Country Status (8)

Country Link
US (2) US5652138A (fi)
EP (1) EP0777497A4 (fi)
JP (1) JPH10505229A (fi)
AU (1) AU706601B2 (fi)
CA (1) CA2195454A1 (fi)
FI (1) FI970198A7 (fi)
NO (1) NO970221L (fi)
WO (1) WO1996002273A1 (fi)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030187247A1 (en) * 1992-09-30 2003-10-02 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
US5652138A (en) * 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
US20060078561A1 (en) * 1994-01-31 2006-04-13 The Trustees Of Boston University Polyclonal antibody libraries
EP1231268B1 (en) 1994-01-31 2005-07-27 Trustees Of Boston University Polyclonal antibody libraries
US7048935B2 (en) 1995-04-27 2006-05-23 The United States Of America As Represented By The Department Of Health And Human Services Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use
US5843882A (en) 1995-04-27 1998-12-01 The United States Of America As Represented By The Department Of Health And Human Services Antiviral proteins and peptides
US6987096B1 (en) 1995-04-27 2006-01-17 The United States Of America As Represented By The Department Of Health And Human Services Antiviral proteins and peptides, DNA coding sequences therefor, and uses thereof
US6193982B1 (en) 1995-04-27 2001-02-27 The United States Of America As Represented By The Department Of Health & Human Services Anti-cyanovirin antibody with an internal image of gp120, a method of use thereof, and a method of using a cyanovirin to induce an immune response to gp120
US6780847B2 (en) 1995-04-27 2004-08-24 The United States Of America As Represented By The Department Of Health And Human Services Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins
US6428790B1 (en) 1995-04-27 2002-08-06 The United States Of America As Represented By The Secretary Department Of Health And Human Services Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use
US6265215B1 (en) * 1996-09-13 2001-07-24 Ludwig Institute For Cancer Research Isolated peptides which complex with HLA-Cw16 and uses thereof
IL140701A0 (en) 1998-07-13 2002-02-10 Univ Texas Cancer treatment methods using antibodies to aminophospholipids
EP2206785A1 (en) 1998-12-31 2010-07-14 Novartis Vaccines and Diagnostics, Inc. Improved expression of HIV polypeptides and production of virus-like particles
JP2003523721A (ja) 1998-12-31 2003-08-12 カイロン コーポレイション 抗原性ｈｉｖｃ型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7883704B2 (en) * 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
US6482928B1 (en) 1999-04-13 2002-11-19 Aventis Pasteur Limited And University Of Toronto Fab′-epitope complex from HIV-1 cross-neutralizing monoclonal antibody 2F5
US20040063605A1 (en) * 2000-08-02 2004-04-01 Jesper Eugen-Olsen Composition and method for the treatment or prevention of hiv infection
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
ATE369427T1 (de) 2001-03-22 2007-08-15 Us Health Glykosylierungsresistente cyanovirine und damit verbundene konjugate, zusammensetzungen, nukleinsäuren, vektoren, wirtszellen, herstellungsverfahren sowie verfahren zur verwendung nichtglykosylierter cyanovirine
US20020146753A1 (en) * 2001-04-06 2002-10-10 Henrik Ditzel Autoantibodies to glucose-6-phosphate isomerase and their participation in autoimmune disease
AU2002305452A1 (en) * 2001-05-08 2002-11-18 Emory University Regulating immine responses using dendritic cells
WO2003004620A2 (en) 2001-07-05 2003-01-16 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
DE60237704D1 (de) * 2001-10-16 2010-10-28 Government Of The Us Secretary Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co-rezeptorkomplexen selektiert werden
US7811992B2 (en) 2002-02-06 2010-10-12 Stasys Technologies, Inc. Anti-infarction molecules
EP1572937B1 (en) 2002-04-09 2012-02-08 The Scripps Research Institute Motif-grafted hybrid polypeptides and uses thereof
WO2003092630A2 (en) * 2002-05-06 2003-11-13 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries
EP1504034B1 (en) * 2002-05-06 2012-12-12 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Identification of novel broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies
US7429360B2 (en) * 2002-05-28 2008-09-30 Autogenomics, Inc. Level-controlled pipette for automated analytic devices
US20040081653A1 (en) * 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
US7597936B2 (en) * 2002-11-26 2009-10-06 University Of Utah Research Foundation Method of producing a pigmented composite microporous material
EP1576351A4 (en) * 2002-11-26 2010-06-23 Univ Utah Res Found MICROPOROUS MATERIALS; METHODS AND ARTICLES FOR LOCALIZING AND QUANTIFYING ANALYTES
WO2004053100A2 (en) * 2002-12-11 2004-06-24 The Scripps Research Institute Immunogenic mutant human immunodeficiency virus gp120 polypeptides, and methods of using same
CA2530166A1 (en) 2003-03-07 2004-09-23 Randolph D. Glickman Antibody-targeted photodynamic therapy
WO2004101738A2 (en) * 2003-05-06 2004-11-25 The Scripps Research Institute Domain-exchanged binding molecules, methods of use and methods of production
US20060035242A1 (en) * 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
JP2007518422A (ja) 2004-01-21 2007-07-12 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデーション 変異体ナトリウムチャンネルＮａν１．７およびそれに関連する方法
WO2005077106A2 (en) * 2004-02-09 2005-08-25 Northeastern University Monoclonal antibody based biomarker discovery and development platform
US20080038280A1 (en) * 2004-10-14 2008-02-14 Government Of The United States Of America A32 Monoclonal Antibody Fusion Proteins For Use As Hiv Inhibitors And Vaccines
EP1807450A2 (en) * 2004-10-29 2007-07-18 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies
EP1831247B1 (en) 2004-12-29 2009-07-01 Seattle Biomedical Research Institute Hetero-oligomeric hiv envelope proteins
CA2594840A1 (en) * 2005-01-13 2006-07-20 Novartis Vaccines And Diagnostics Inc. Elisa assays using prion-specific peptide reagents
WO2006076683A2 (en) * 2005-01-13 2006-07-20 Novartis Vaccines And Diagnostics Inc. Isolation and detection of pathogenic prions
EP1989326A4 (en) 2006-01-17 2009-09-30 Health Research Inc BIO-HETERODUPLEX TRACKING TEST
US8470965B2 (en) * 2006-03-01 2013-06-25 University Of Utah Research Foundation Methods and compositions related to cyclic peptide synthesis
US9365622B2 (en) * 2006-03-01 2016-06-14 University Of Utah Research Foundation Methods and compositions related to cyclic peptide synthesis
US7492312B2 (en) * 2006-11-14 2009-02-17 Fam Adly T Multiplicative mismatched filters for optimum range sidelobe suppression in barker code reception
WO2008085794A2 (en) * 2007-01-03 2008-07-17 Burnham Institute For Medical Research Methods and compositions related to clot binding compounds
EP2115173B1 (en) 2007-01-08 2011-09-21 Government of the USA, as Represented by the Secretary, Department of Health and Human Services Slco1b3 genotype
KR20150038227A (ko) * 2007-01-16 2015-04-08 애브비 인코포레이티드 건선의 치료방법
RU2476442C2 (ru) * 2007-03-29 2013-02-27 Эббот Лэборетриз Кристаллические антитела против il-12 человека
WO2009023306A2 (en) 2007-05-09 2009-02-19 Burnham Institute For Medical Research Targeting host proteinases as a therapeutic strategy against viral and bacterial pathogens
EP2164957B1 (en) 2007-05-23 2017-07-12 The UAB Research Foundation Detoxified pneumococcal neuraminidase and uses thereof
US20100239596A1 (en) * 2007-08-22 2010-09-23 University Of Southern California Grp78 and tumor angiogenesis
CA2697957A1 (en) 2007-08-28 2009-03-12 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
WO2009032693A2 (en) 2007-08-28 2009-03-12 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
EP2268664B1 (en) * 2007-12-03 2017-05-24 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Doc1 compositions and methods for treating cancer
US8557239B2 (en) 2009-09-14 2013-10-15 Abbvie Inc. Methods for treating psoriasis using antibodies that bind to the P40 subunit of IL-12 and/or IL-23
TWI461210B (zh) 2008-03-18 2014-11-21 Abbvie Inc 治療牛皮癬的方法
CN102083450A (zh) * 2008-04-30 2011-06-01 诺华有限公司 致病性构象异构体的分析
WO2010019120A1 (en) 2008-08-15 2010-02-18 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health S0x9, prostaglandin d2 and retinoic acid for treating pigmentary conditions and melanoma
US20120128684A1 (en) 2008-08-25 2012-05-24 Burnham Institute For Medical Research Conserved Hemagglutinin Epitope, Antibodies to the Epitope and Methods of Use
JP2012510468A (ja) * 2008-11-28 2012-05-10 アボット・ラボラトリーズ 安定な抗体組成物およびこれを安定させるための方法
US20120070443A1 (en) 2008-12-02 2012-03-22 University Of Utah Research Foundation Pde1 as a target therapeutic in heart disease
WO2011020107A2 (en) 2009-08-14 2011-02-17 Georgetown University Compositions and methods for detection and treatment of breast cancer
EP2485768A1 (en) 2009-10-07 2012-08-15 Sanford-Burnham Medical Research Institute Methods and compositions related to clot-binding lipid compounds
EP2512497A1 (en) 2009-12-18 2012-10-24 Sanford-Burnham Medical Research Institute Methods and compositions related to clot-binding compounds
US20110177107A1 (en) 2010-01-14 2011-07-21 Haplomics, Inc. Predicting and reducing alloimmunogenicity of protein therapeutics
US20110207789A1 (en) 2010-02-19 2011-08-25 Ye Fang Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents
EP3187585A1 (en) 2010-03-25 2017-07-05 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
US20110293629A1 (en) 2010-05-14 2011-12-01 Bastid Jeremy Methods of Treating and/or Preventing Cell Proliferation Disorders with IL-17 Antagonists
US9051619B2 (en) 2011-03-25 2015-06-09 Florida Agricultural and Mechanical University (FAMU) Methods and compositions for prostate cancer metastasis
ES2667425T3 (es) 2011-06-10 2018-05-10 Oregon Health & Science University Glucoproteínas y vectores recombinantes de CMV
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
US20150175678A1 (en) * 2012-06-15 2015-06-25 Beth Israel Deaconess Medical Center, Inc. IgA CD4i ANTIBODIES AND METHODS OF TREATMENT USING SAME
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
US20140094383A1 (en) 2012-10-02 2014-04-03 Ohio State Innovation Foundation Tethered Lipoplex nanoparticle Biochips And Methods Of Use
US9783576B2 (en) 2013-06-11 2017-10-10 Sanford-Burnham Medical Research Institute Compositions and methods for targeted endometriosis treatment
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
US9481729B2 (en) 2013-09-11 2016-11-01 The University Of Hong Kong Anti-HER2 and anti-IGF-IR BI-specific antibodies and uses thereof
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9840555B2 (en) 2013-11-04 2017-12-12 Li-Te Chin Method for producing human monoclonal antibodies that binds to at least one part of HMGB1
WO2016018665A1 (en) 2014-07-31 2016-02-04 Uab Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
CN108779168A (zh) 2015-12-05 2018-11-09 沃迪奥斯大学医院中心 Hiv结合剂
CA3039532A1 (en) 2016-10-05 2018-04-12 University Of Central Florida Research Foundation, Inc. Methods and compositions related to nk cell and anti-pdl1 cancer therapies
WO2018183488A1 (en) 2017-03-28 2018-10-04 Ohio State Innovation Foundation Human pd1 peptide vaccines and uses thereof
WO2019055618A1 (en) 2017-09-15 2019-03-21 Arizona Board Of Regents On Behalf Of Arizona State University METHODS OF CLASSIFYING RESPONSES TO ANTICANCER IMMUNOTHERAPY
WO2019118686A1 (en) 2017-12-13 2019-06-20 North Carolina State University Compositions comprising chemotherapeutic agents and checkpoint inhibitors and methods of use
EP3813884B1 (en) 2018-06-29 2024-09-18 North Carolina State University In situ sprayed bioresponsive immunotherapeutic gel for post-surgical treatment
WO2020012435A1 (en) 2018-07-13 2020-01-16 Lausanne University Hospital Hiv binding agents
US20220267435A1 (en) 2018-10-03 2022-08-25 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Covalent adaptor synnotch and chimeric antigen receptors (cars) for programmable antigen-targeting
EP4400840A3 (en) 2018-12-27 2025-02-12 University Of Utah Research Foundation Compositions and methods useful in detecting and treating multiple sclerosis and other demyelinating diseases
KR20210133225A (ko) * 2019-01-28 2021-11-05 사이포스 바이오사이언시스 인코포레이티드 부착된 이종 분자를 car-세포의 비천연 nkg2d 수용체에 선택적으로 전달하는 변형된 비천연 nkg2d 리간드
WO2020206233A1 (en) 2019-04-04 2020-10-08 Vanderbilt University Therapeutic antibodies for treating lung cancer
US11660330B2 (en) 2019-06-21 2023-05-30 H. Lee Moffitt Cancer Center And Research Institute, Inc. Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy
WO2021009697A2 (en) 2019-07-15 2021-01-21 Lausanne University Hospital Hiv binding agents
WO2021067550A1 (en) 2019-10-02 2021-04-08 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer
CN115485392A (zh) 2020-01-24 2022-12-16 范德比尔特大学 用于鉴别配体阻断性抗体及用于确定抗体效价的方法
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
EP4146327A1 (en) 2020-05-08 2023-03-15 Novocure GmbH Compositions and methods of applying alternating electric fields to pluripotent stem cells
EP4153590A4 (en) 2020-05-21 2024-06-19 Ohio State Innovation Foundation FUNCTIONAL LIPID DERIVATIVES AND THEIR USES
EP4288456B1 (en) 2021-02-03 2024-09-18 Mythic Therapeutics, Inc. Anti-met antibodies and uses thereof
TW202448962A (zh) 2023-02-23 2024-12-16 美商翰森生物有限責任公司 抗體、抗原結合片段和使用方法
WO2025245128A1 (en) 2024-05-20 2025-11-27 Mythic Therapeutics, Inc. Antibody drug conjugates and therapeutic uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5652138A (en) * 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus

Also Published As

Publication number Publication date
AU2970095A (en) 1996-02-16
FI970198A7 (fi) 1997-03-17
US5804440A (en) 1998-09-08
EP0777497A1 (en) 1997-06-11
US5652138A (en) 1997-07-29
CA2195454A1 (en) 1996-02-01
EP0777497A4 (en) 1998-01-07
NO970221D0 (no) 1997-01-17
FI970198A0 (fi) 1997-01-17
JPH10505229A (ja) 1998-05-26
NO970221L (no) 1997-03-18
AU706601B2 (en) 1999-06-17
WO1996002273A1 (en) 1996-02-01

Similar Documents

Publication Publication Date Title
FI970198L (fi) Ihmisen immuunikatoviruksen vastaiset neutraloivat ihmisen monoklonaaliset vasta-aineet
FI951488L (fi) Ihmisen immuunikatoviruksen vastaiset ihmisen neutraloivat monoklonaaliset vasta-aineet
FI951164L (fi) Respiratory syncytial -viruksen vastaiset neutraloivat ihmisen monoklonaaliset vasta-aineet
DK1516629T3 (da) Humaniseret anti-CD-11a antibodies
NO955167D0 (no) Monoklonalt anti-
BR9605563A (pt) Andador dobrável
NO980915L (no) Rekombinante anti-CD4-antistoff egnet for human terapi
FI970301L (fi) Spesifisen immunoglobuliinin määrittäminen käyttäen useampaa antigeenia
NO975621L (no) Höyaffinitets-humane monoklonale antistoff spesifikke for RSV F-protein
BR9106394A (pt) Anticorpos anti-icam-1 quimericos humanizados,processos de preparacao e uso
DE69609959D1 (de) Abgasbehandlung
FI945865A7 (fi) Glykoprofeiini P:lle kohdistettuja monoklonaalisia vasta-aineita
DE69738312D1 (de) Hepatitis b monoklonale antikörper
AU7203194A (en) Bispecific human monoclonal antibodies specific for human immunodeficiency virus
EP0967993A4 (en) ANTI-COCAINE VACCINE
ATE253641T1 (de) Antigenische präparationen
BR9509902A (pt) Fragmentos de anticorpos monoclonais apresentando atividade imunosupressante
DE69322847D1 (de) Monoklonaler Antikörper gegen menschliches Ceruloplasmin
ATA98795A (de) Anti-plasma-antikörper-präparation
FI895829A7 (fi) Ihmisen monoklonaaliset vasta-aineet rabiesvirusta vastaan
NL300165I2 (nl) Babesiavaccin.
BR9709080A (pt) Anticorpo monoclonal anti-MP52 humano
KR970007784U (ko) 미꾸라지 통발
ITMI950511A0 (it) Fotodensitometro parallelo perfezionato
KR970037926U (ko) 후드 스톱퍼